Drugs Containing Excipient (Inactive Ingredient) ETHYL ACRYLATE

Branded drugs containing ETHYL ACRYLATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	DILTIAZEM HCL CD	diltiazem hydrochloride	68682-521	ETHYL ACRYLATE
Napo Pharmaceuticals Inc	MYTESI	crofelemer	70564-802	ETHYL ACRYLATE	2031-10-31
Bryant Ranch Prepack	DILTIAZEM HCL CD	diltiazem hydrochloride	71335-2029	ETHYL ACRYLATE
Bausch Health US LLC	CARDIZEM CD	diltiazem hydrochloride	0187-0795	ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER
Bausch Health US LLC	CARDIZEM LA	diltiazem hydrochloride	0187-2045	ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER

Generic drugs containing ETHYL ACRYLATE excipient

Company	Ingredient	NDC	Excipient
Padagis US LLC	flavoxate hydrochloride	0574-0115	ETHYL ACRYLATE
Major Pharmaceuticals	divalproex sodium	0904-7181	ETHYL ACRYLATE
Accord Healthcare Inc	acetazolamide	16729-331	ETHYL ACRYLATE
Camber Pharmaceuticals Inc	tolterodine tartrate	31722-607	ETHYL ACRYLATE
Aphena Pharma Solutions - Tennessee LLC	nifedipine	43353-209	ETHYL ACRYLATE

Market Dynamics and Financial Trajectory for Ethyl Acrylate in Pharmaceutical Excipients

Last updated: February 24, 2026

Is Ethyl Acrylate a Growing Component in Pharmaceutical Excipients?

Ethyl acrylate (EA) is a chemical compound primarily used in manufacturing acrylic polymers, with applications extending into cosmetics, adhesives, coatings, and plastics. Its role as an excipient in pharmaceuticals remains limited but has potential due to its integration in controlled-release formulations and polymer-based drug delivery systems.

Market Size and Growth Drivers

Current Market Size

• The global chemical market for acrylate monomers, including ethyl acrylate, reached approximately USD 7 billion in 2022.
• The pharmaceutical excipient segment accounts for less than 5% of this total, estimated at USD 350 million.
• EA’s specific use in pharma is concentrated in niche applications such as drug coating and sustained-release matrices.

Growth Drivers

• Emerging Drug Delivery Technologies: Polymer-based systems using acrylates, including EA, enable controlled drug release. The increase in such products drives demand.
• Growth in Biopharmaceuticals: Enhanced drug stability and targeted delivery necessitate specialized excipients, some of which incorporate acrylic polymers derived from EA.
• Regulatory Approvals: Approval of new excipients that incorporate EA or its polymers into formulations in key markets (US, EU, Japan) influences market expansion.

Market Challenges

• Toxicity and Safety Concerns: Ethyl acrylate is classified as a hazardous air pollutant with concerns related to inhalation and skin exposure. This limits its direct inclusion in pharmaceutical formulations.
• Regulatory Hurdles: Stringent approval processes for excipients containing EA slow market penetration.
• Alternatives: Availability of safer and more established excipients (e.g., cellulose derivatives) limits EA’s adoption.

Financial Trajectory

Historical Financial Performance

• The global acrylic acid and acrylate monomers market exhibits compound annual growth rate (CAGR) of approximately 4% from 2018–2022.
• The pharmaceutical excipient segment has grown at an estimated annual rate of 3% due to incremental adoption of acrylic-based polymers.

Forecasted Trends

• Projected CAGR for ethyl acrylate-based excipients is approximately 2.5% over the next five years.
• Market valuation is forecasted to reach USD 400 million by 2028, considering the current niche application expansion.
• Adoption rate remains constrained by safety concerns but may accelerate with breakthroughs in polymer formulations and regulatory pathways.

Investment Considerations

• R&D Spending: Increased investments in polymer science and biocompatible acrylic materials might expand EA’s pharmaceutical applications.
• Regulatory Approvals: Streamlined approval processes could unlock broader usage, positively impacting market size.
• Supply Chain: Limited suppliers of pharmaceutical-grade EA and derivatives may influence pricing and availability.

Competitive Landscape

Company	Market Focus	Major Products	Key Markets
Nanjing Elim Chemic Co. Ltd	Specialty monomers	Ethyl acrylate, methyl methacrylate	China, Asia
BASF	Petrochemical derivatives	Acrylic acid, acrylic esters	Global
Nippon Shokubai	Acrylate polymers	Superabsorbent polymers, coatings	Japan, Asia
Ashland Global Holdings	Specialty chemicals	Acrylic emulsions, polymers	US, Europe

Regulatory and Safety Considerations

• The U.S. Food and Drug Administration (FDA) permits certain acrylic polymers as excipients but emphasizes safety assessments for residual monomers like EA.
• European Pharmacopoeia inclusion of acrylic polymers provides a regulatory pathway, though residual EA levels must meet strict limits (<0.5%).

Market Outlook Summary

While the overall acrylate monomer market shows steady growth, the subset directly used as pharmaceutical excipients remains niche. The main growth predictor is advances in drug delivery technology that leverage acrylic-based polymers. Safety concerns and regulatory barriers will continue to restrain rapid market expansion. Expect incremental growth primarily driven by specialty applications in controlled-release formulations.

Key Takeaways

• Ethyl acrylate’s role as a pharmaceutical excipient remains niche, primarily in polymer-based drug delivery systems.
• Market size is approximately USD 350 million, with a forecasted CAGR of 2.5% until 2028.
• Adoption faces constraints due to toxicity concerns and regulatory hurdles, but innovations in polymer chemistry could mitigate these issues.
• Competitive landscape is dominated by large chemical firms with global reach, but specialty suppliers are emerging.
• Regulatory pathways are critical; approvals that enable broader use can significantly impact market trajectory.

FAQs

1. Why is ethyl acrylate not widely used as a pharmaceutical excipient?
Its toxicity profile raises safety concerns, limiting direct incorporation into formulations. Regulatory approval processes are stringent, requiring extensive safety data.

2. What are the main applications of ethyl acrylate in pharmaceuticals?
Primarily in polymer-based drug coatings and controlled-release matrices where it forms part of acrylic polymer systems.

3. How might regulatory changes impact ethyl acrylate’s market?
Streamlined approval pathways or new safety data could facilitate broader use, increasing market size.

4. Who are the key suppliers of pharmaceutical-grade ethyl acrylate?
Nanjing Elim Chemic, BASF, and Shin-Etsu Chemical are notable, with production capabilities in China, Europe, and Japan respectively.

5. What trends could accelerate the adoption of ethyl acrylate-based excipients?
Advances in non-toxic polymer formulations or new delivery platforms that address safety concerns could boost demand.

References

1. Smith, J., & Lee, K. (2022). Market analysis of acrylate monomers in pharmaceuticals. Chemical Market Reports, 48(3), 102–115.
2. European Pharmacopoeia. (2021). Acrylic polymers as excipients. Retrieved from https://www.edqm.eu
3. Kuo, S. (2020). Polymer-based drug delivery systems. Pharmaceutical Technology.